BORTEZOMIB
Manufacturer: Hospira, Inc.
Score: 141.0
Bortezomib is a proteasome inhibitor used for the treatment of adult patients with multiple myeloma and mantle cell lymphoma. It is administered intravenously or subcutaneously, with dosing regimens varying based on the specific condition being treated and patient factors. Key clinical findings indicate efficacy in achieving response and improving time to progression in relapsed multiple myeloma and previously untreated mantle cell lymphoma. Important safety information includes warnings about peripheral neuropathy, hypotension, cardiac toxicity, and pulmonary toxicity, among others. Contraindications include hypersensitivity to bortezomib, boron, or mannitol, and intrathecal administration. Dosing recommendations are provided for different conditions, with considerations for dose adjustments based on toxicity and special populations such as pregnancy, nursing mothers, pediatric, and geriatric use.
Peripheral neuropathy, hypotension, cardiac toxicity, and pulmonary toxicity are potential adverse reactions
Dose adjustments may be necessary based on toxicity, with reductions to 1 mg/m^2 or 0.7 mg/m^2
1.3 mg/m^2 administered intravenously or subcutaneously twice weekly for 2 weeks, followed by a 10-day rest period
Not established
1.3 mg/m^2 administered intravenously or subcutaneously twice weekly for 2 weeks, followed by a 10-day rest period
Not established